48 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
19 Mar 24
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
4:17pm
in the adolescent and adult trial, which will expedite and further inform our clinical development and regulatory strategy for the dose expansion portion … 30 years of experience in regulatory strategy and product development in the biopharmaceutical space. She will continue to lead the Company’s
424B3
TSHA
Taysha Gene Therapies Inc
11 Sep 23
Prospectus supplement
4:01pm
be forced to curtail our planned operations and the pursuit of our growth strategy.
We have a limited operating history and no history of commercializing … for commercial use;
our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods
424B3
j663q
4 May 23
Prospectus supplement
4:02pm
PRE 14A
8dsqbr 4d
27 Apr 23
Preliminary proxy
4:03pm
8-K
EX-99.1
vy570nsa2foplgmp
22 Dec 22
Taysha Gene Therapies Announces Executive Leadership Changes
4:08pm
424B5
lkrz65hd2scp8ex
27 Oct 22
Prospectus supplement for primary offering
5:13pm
424B5
y2mwnqyidfwkwitir1
25 Oct 22
Prospectus supplement for primary offering
4:35pm
8-K
EX-99.1
szmk7u13dvid1z d0i
25 Oct 22
Astellas and Taysha Gene Therapies Announce
8:01am